Cytokinetics to Announce Third Quarter Results on October 31, 2019 – Yahoo Finance

Posted: Published on October 24th, 2019

This post was added by Alex Diaz-Granados

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics website at http://www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 9440838.

An archived replay of the webcast will be available via Cytokinetics website until November 7, 2019. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 9440838 from October 31, 2019 at 7:30 PM Eastern Time until November 7, 2019.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast skeletal muscle troponin activator (FSTA) for diseases of neuromuscular dysfunction, including SMA and ALS. Astellas holds an exclusive worldwide license to develop and commercialize reldesemtiv. Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").Cytokineticsdisclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act'sSafe Harborfor forward-looking statements. Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related toCytokinetics'business outlined inCytokinetics'filings with theSecurities and Exchange Commission. Forward-looking statements are not guarantees of future performance, andCytokinetics'actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements thatCytokineticsmakes in this press release speak only as of the date of this press release.Cytokineticsassumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Story continues

Contact:CytokineticsDiane WeiserVice President, Corporate Communications, Investor Relations(650) 624-3060

Excerpt from:

Cytokinetics to Announce Third Quarter Results on October 31, 2019 - Yahoo Finance

Related Posts
This entry was posted in Cardiomyopathies. Bookmark the permalink.

Comments are closed.